These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 29698175)

  • 1. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico.
    Neslusan C; Teschemaker A; Johansen P; Willis M; Valencia-Mendoza A; Puig A
    Value Health Reg Issues; 2015 Dec; 8():8-19. PubMed ID: 29698175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
    Sabapathy S; Neslusan C; Yoong K; Teschemaker A; Johansen P; Willis M
    J Popul Ther Clin Pharmacol; 2016; 23(2):e151-68. PubMed ID: 27463416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.
    Neslusan C; Teschemaker A; Willis M; Johansen P; Vo L
    Diabetes Ther; 2018 Apr; 9(2):565-581. PubMed ID: 29411292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC; Samyshkin Y; Langer J; Palmer JL
    J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
    Stafford S; Bech PG; Fridhammar A; Miresashvili N; Nilsson A; Willis M; Liu A
    Appl Health Econ Health Policy; 2022 Jul; 20(4):543-555. PubMed ID: 35344191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China.
    Hou X; Wan X; Wu B
    Front Pharmacol; 2019; 10():480. PubMed ID: 31143117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting.
    Shao YL; Yee KH; Koh SK; Wong YF; Yeoh LY; Low S; Sum CF
    Singapore Med J; 2018 May; 59(5):251-256. PubMed ID: 29022040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India.
    Gupta V; Willis M; Johansen P; Nilsson A; Shah M; Mane A; Neslusan C
    Value Health Reg Issues; 2019 May; 18():65-73. PubMed ID: 30502662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus.
    Ektare VU; Lopez JM; Martin SC; Patel DA; Rupnow MF; Botteman MF
    Am J Manag Care; 2014 Oct; 20(10 Suppl):S204-15. PubMed ID: 25495002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
    Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Duh MS; Lefebvre P
    J Med Econ; 2015 Feb; 18(2):113-25. PubMed ID: 25350645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
    Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
    Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L; Zhao FL; Li SC
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL; Minshall ME
    Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
    Xie X; Vondeling H
    Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden.
    Kiadaliri AA; Gerdtham UG; Eliasson B; Carlsson KS
    Diabetes Ther; 2014 Dec; 5(2):591-607. PubMed ID: 25213800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome.
    Davies MJ; Merton KW; Vijapurkar U; Balis DA; Desai M
    Diabetes Metab Syndr Obes; 2017; 10():47-55. PubMed ID: 28184166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
    Roussel R; Martinez L; Vandebrouck T; Douik H; Emiel P; Guery M; Hunt B; Valentine WJ
    J Med Econ; 2016; 19(2):121-34. PubMed ID: 26413789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.